TROSPIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Trospium Chloride patents expire, and what generic alternatives are available?
Trospium Chloride is a drug marketed by Actavis Labs Fl Inc, Amta, Granules, Padagis Us, Upsher Smith Labs, Apotex, Glenmark Generics, Heritage Pharms Inc, Invagen Pharms, and Zameer Pharms. and is included in eleven NDAs.
The generic ingredient in TROSPIUM CHLORIDE is trospium chloride. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trospium Chloride
A generic version of TROSPIUM CHLORIDE was approved as trospium chloride by GLENMARK GENERICS on August 13th, 2010.
Summary for TROSPIUM CHLORIDE
Recent Clinical Trials for TROSPIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Texas Medical Branch, Galveston | Early Phase 1 |
Amiri Hospital | N/A |
Mansoura University | N/A |
Pharmacology for TROSPIUM CHLORIDE
Drug Class | Cholinergic Muscarinic Antagonist |
Mechanism of Action | Cholinergic Muscarinic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for TROSPIUM CHLORIDE
Paragraph IV (Patent) Challenges for TROSPIUM CHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SANCTURA XR | Extended-release Capsules | trospium chloride | 60 mg | 022103 | 1 | 2009-03-02 |